medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2016, Número 3

<< Anterior

Rev Invest Clin 2016; 68 (3)


G80A single nucleotide polymorphism in reduced folate carrier-1 gene in a mexican population and its impact on survival in patients with acute lymphoblastic leukemia

Candelaria M, Ojeda J, Gutiérrez-Hernández O, Taja-Chayeb L, Vidal-Millán S, Dueñas-González A

Idioma: Ingles.
Referencias bibliográficas: 40
Paginas: 154-162
Archivo PDF: 836.12 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 2015; 29:243-9.

  2. Candelaria M, Taja-Chayeb L, Arce-Salinas C, Vidal-Millan S, Serrano-Olvera A, Dueñas-Gonzalez A. Genetic determinants of cancer drug efficacy and toxicity. Practical considerations and perspectives. Anticancer Drugs. 2005;16:923-33.

  3. Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59:2532-5.

  4. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA. 1999;96:6914-19.

  5. Hider I, Bruce N, Thomson W. The pharmacogenetics of methotrexate. Rheumatology. 2007;46:1520-4.

  6. Payne K, Newman W, Fargher E, Tricker K, Bruce IN, Ollier WE. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology. 2007;46:727-9.

  7. Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacology. 2001;52:345-7.

  8. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47:247-57.

  9. Stanisławska-Sachadyn A, Mitchell LE, Woodside JV, et al. The reduced folate carrier (SLC19A1) c.80G>A polymorphism is associated with red cell folate concentrations among women. Ann Hum Genet. 2009;73:484-91.

  10. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266-73.

  11. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Act. 2002;1587:164-73.

  12. de Deus DM, de Lima EL, Seabra Silva RM, Leite EP, Cartaxo Muniz MT. Influence of methylenetetrahydrofolate reductase C677T, A1298C, and G80A polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia. Leuk Res Treatment. 2012;2012:292043.

  13. Antonio-Vejar A, Del Moral-Hernández O1, Alarcón-Romero LC1, et. al. Ethnic variation of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate-reductase (MTHFR) gene in southwestern Mexico. Genet Mol Res. 2014;13:7950-7.

  14. Ramos MA, Mares RE, Avalos ED, et. al. Pharmacogenetic screening of N-acetyltransferase 2, thiopurine s-methyltransferase, and 5,10-methylene-tetrahydrofolate reductase polymorphisms in Northwestern Mexicans. Genet Test Mol Biomarkers. 2011; 15:351-5.

  15. Guéant-Rodriguez RM, Guéant JL, Debard R, et.al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am J Clin Nutr. 2006;83:701-7.

  16. Robien K, Ulrich CM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE mini-review. Am J Epidemiol. 2003;157:571-82.

  17. Tas¸bas¸ O, Borman P, Gürhan Karabulut H, Tükün A, Yorgancıog˘ lu R. The frequency of A1298C and C677T polymorphisms of the methylenetetrahydrofolate gene in Turkish patients with rheumatoid arthritis: Relationship with methotrexate toxicity. Open Rheumatol J. 2011;5:30-5.

  18. NCCN Guidelines Version 2.0 2015. Acute Lymphoblastic Leukemia. Available at: http://www.nccn.org/professionals/physician_ gls/pdf/all.pdf (Accessed January 5, 2016).

  19. Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-61.

  20. Samara SA, Irshaid Y, Mustafa KN. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014;52:746-55.

  21. Huang X, Gao Y, He J, et al. The association between RFC1 G80A polymorphism and cancer susceptibility: Evidence from 33 studies. J Cancer. 2016;7:144-52.

  22. Leyva-Vázquez MA, Organista-Nava J, Gómez-Gómez Y, Contreras- Quiroz A, Flores-Alfaro E, Illades-Aguiar B. Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia. J Investig Med. 2012;60:1064-7.

  23. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylene tetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med. 2003;11:593-600.

  24. Mandola MV, Stoehlmacher J, Zhang W, et al. A 6bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics. 2004;14:319-427.

  25. Yates Z, Lucock M. G80A reduced folate carrier SNP modulates cellular uptake of folate and affords protection against thrombosis via a non homocysteine related mechanism. Life Sci. 2005; 77:2735-42.

  26. Dervieux T, Kremer J, Lein DO, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamyl hydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004;14:733-9.

  27. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766-74.

  28. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006;54: 1087-95.

  29. Ranganathan P, Culverhouse R, Marsh S, et al. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics. 2004;5:559-69.

  30. Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res. 2001;7:3416-22.

  31. Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicenter crossectional observational study. Ann Rheum Dis. 2005;64:1180-5.

  32. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095-103.

  33. de Deus DM, de Lima EL, Seabra Silva RM, Leite EP, Cartaxo Muniz MT. Influence of methylenetetrahydrofolate reductase C677T, A1298C, and G80A polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia. Leuk Res Treatment. 2012;2012:292043.

  34. Ruiz-Argüelles GJ, Coconi-Linares LN, Garcés-Eisele J, Reyes- Nuñez V. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology. 2007;12:387-91.

  35. Cui G, Ding H, Xu Y, Li B, Wang DW. Applications of the method of high resolution melting analysis for diagnosis of Leber’s disease and the three primary mutation spectrum of LHON in the Han Chinese population. Gene. 2013;512:108-12.

  36. Frueh FW, Noyer-Weidner M. The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics. Clin Chem Lab Med. 2003;41:452-61.

  37. Taja-Chayeb L, Vidal-Millán S, Gutiérrez O, Ostrosky-Wegman P, Dueñas-González A, Candelaria M. Importance of the polymorphisms of the Thiopurine S-methyltransferase Gene (TMPT) determination in Mexican Mestizo patients with acute lymphoblastic leukemia (ALL). Med Oncol. 2008;25:56-62.

  38. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: A review. Hum Mutat. 2001;17:439-74.

  39. O’Donovan MC, Oefner PJ, Roberts SC, et al. Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. Genomics. 1998;52:44-9.

  40. Steinmetz LM, Davis RW. High-density arrays and insights into genome function. Biotech Genet Eng Rev. 2000;17:109-47.




2020     |     www.medigraphic.com